Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 6
1974 1
1979 2
1981 1
1982 1
1983 3
1984 4
1985 2
1986 7
1987 5
1988 5
1989 4
1990 2
1991 2
1992 5
1993 1
1994 5
1996 3
1997 5
1999 1
2000 5
2001 1
2002 2
2006 2
2008 2
2010 1
2011 1
2012 1
2013 4
2014 5
2015 1
2016 5
2017 4
2018 1
2019 2
2021 7
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m delange[Author] (12 results)?
Brain charts for the human lifespan.
Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, Adler S, Alexopoulos GS, Anagnostou E, Areces-Gonzalez A, Astle DE, Auyeung B, Ayub M, Bae J, Ball G, Baron-Cohen S, Beare R, Bedford SA, Benegal V, Beyer F, Blangero J, Blesa Cábez M, Boardman JP, Borzage M, Bosch-Bayard JF, Bourke N, Calhoun VD, Chakravarty MM, Chen C, Chertavian C, Chetelat G, Chong YS, Cole JH, Corvin A, Costantino M, Courchesne E, Crivello F, Cropley VL, Crosbie J, Crossley N, Delarue M, Delorme R, Desrivieres S, Devenyi GA, Di Biase MA, Dolan R, Donald KA, Donohoe G, Dunlop K, Edwards AD, Elison JT, Ellis CT, Elman JA, Eyler L, Fair DA, Feczko E, Fletcher PC, Fonagy P, Franz CE, Galan-Garcia L, Gholipour A, Giedd J, Gilmore JH, Glahn DC, Goodyer IM, Grant PE, Groenewold NA, Gunning FM, Gur RE, Gur RC, Hammill CF, Hansson O, Hedden T, Heinz A, Henson RN, Heuer K, Hoare J, Holla B, Holmes AJ, Holt R, Huang H, Im K, Ipser J, Jack CR Jr, Jackowski AP, Jia T, Johnson KA, Jones PB, Jones DT, Kahn RS, Karlsson H, Karlsson L, Kawashima R, Kelley EA, Kern S, Kim KW, Kitzbichler MG, Kremen WS, Lalonde F, Landeau B, Lee S, Lerch J, Lewis JD, Li J, Liao W, Liston C, Lombardo MV, Lv J, Lynch C,… See abstract for full author list ➔ Bethlehem RAI, et al. Among authors: delarue m. Nature. 2022 Apr;604(7906):525-533. doi: 10.1038/s41586-022-04554-y. Epub 2022 Apr 6. Nature. 2022. PMID: 35388223 Free PMC article.
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Peyrade F, et al. Among authors: delarue r. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7. Lancet Oncol. 2011. PMID: 21482186 Clinical Trial.
All patients received six cycles of rituximab combined with low-dose CHOP (R-miniCHOP) at 3-week intervals. Patients received 375 mg/m(2) rituximab, 400 mg/m(2) cyclophosphamide, 25 mg/m(2) doxorubicin, and 1 mg vincristine on day 1 of each cycle, and 40 mg/ …
All patients received six cycles of rituximab combined with low-dose CHOP (R-miniCHOP) at 3-week intervals. Patients received 375 mg/m …
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Among authors: delarue r. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Bachy E, et al. Among authors: delarue r. J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29. J Clin Oncol. 2022. PMID: 34843406 Clinical Trial.
All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m(2), was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. ...
All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m(2), was administered intravenously over a 4-hour peri …
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. Among authors: delarue r. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
Characteristics of subjective cognitive decline associated with amyloid positivity.
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer's Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group; Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Janssen O, et al. Among authors: delarue m. Alzheimers Dement. 2022 Oct;18(10):1832-1845. doi: 10.1002/alz.12512. Epub 2021 Dec 8. Alzheimers Dement. 2022. PMID: 34877782 Free PMC article.
Lymphome non-Hodgkinien de l'enfant : prise en charge chirurgicale lors d'un tableau abdominal révélateur: Recommandations du « Comité lymphome » de la Société française de lutte contre les cancers de l'enfant et de l'adolescent (SFCE).
Delarue A, Bergeron C, Mechinaud-Lacroix F, Coze C, Raphael M, Patte C, Pour le Comité Lymphome de la Sfce. Delarue A, et al. J Chir (Paris). 2008 Oct;145(5):454-8. doi: 10.1016/S0021-7697(08)74655-6. Epub 2009 Jan 28. J Chir (Paris). 2008. PMID: 22793520 French.
A. Delarue, C. Bergeron, F. Mechinaud-Lacroix, C. Coze, M. Raphael, C. Patte, pour le " Comite Lymphome " de la SFCE Over the past two decades, dramatic improvements in the treatment of children with Non-Hodgkin's Lymphoma have led to cure rates close to 90%, even in advan …
A. Delarue, C. Bergeron, F. Mechinaud-Lacroix, C. Coze, M. Raphael, C. Patte, pour le " Comite Lymphome " de la SFCE Over the past tw …
Clinical pathways in the management of the obese: Pre- and postoperative aspects.
Guillerme S, Delarue J, Thereaux J. Guillerme S, et al. Among authors: delarue j. J Visc Surg. 2023 Apr;160(2S):S15-S21. doi: 10.1016/j.jviscsurg.2022.12.009. Epub 2023 Jan 30. J Visc Surg. 2023. PMID: 36725452 Review.
PREOPERATIVE ASPECTS: BS should be proposed only after failure of well-conducted medical treatment and is intended for patients whose body mass index (BMI) is 40kg/m(2) or for those with BMI 35kg/m(2) who also have co-morbidities amenable to improvement, and in whom …
PREOPERATIVE ASPECTS: BS should be proposed only after failure of well-conducted medical treatment and is intended for patients whose body m …
PA- and NP-led Ommaya clinics to manage leptomeningeal carcinomatosis.
Leese EN, Weeder JL, Manikowski JJ, DeLaRue AM, Conger AR, Mahadevan A, Vogel VG, Mongelluzzo GJ, Gatson NTN. Leese EN, et al. Among authors: delarue am. JAAPA. 2021 Dec 1;34(12):35-41. doi: 10.1097/01.JAA.0000800264.81721.3d. JAAPA. 2021. PMID: 34772854
111 results